Eberconazole

• UNSPSC Description:

  Eberconazole is a dichlorinated imidazole derivative with antifungal activity. Eberconazole is more effective than Clotrimazole (HY-10882), Ketoconazole (HY-B0105), and Miconazole (HY-B0454). Eberconazole has potential for the study of dermatophytosis[1][2].

• Target Antigen:

  Fungal

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/eberconazole.html

• Solubility:

  10 mM in DMSO

• Smiles:

  ClC1=CC(CCC2=C(C3N4C=NC=C4)C=CC=C2)=C3C(Cl)=C1

• Molecular Weight:

  329.22

• References & Citations:

  [1]Fernández-Torres B, et al. In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes. J Clin Microbiol. 2003;41(11):5209-5211. |[2]Moodahadu L S, et al. Preclinical pharmacological profile of Eberconazole: A review and update[J]. Muller Journal of Medical Sciences and Research, 2014, 5(2): 159-165.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  128326-82-9